Quick Takeaways
- MPM BIOVENTURES 2018, L.P. filed SCHEDULE 13D for AKTIS ONCOLOGY, INC. Common Stock (AKTSQ).
- Disclosed ownership: 19%.
- Date of event: 12 Jan 2026.
MPM BIOVENTURES 2018, L.P. - 12 Jan 2026 SCHEDULE 13D Report for AKTIS ONCOLOGY, INC. Common Stock (AKTSQ)
- Filing Manager
- MPM BIOVENTURES 2018, L.P.
- Reporting Manager
- ANSBERT GADICKE
- Security
- AKTIS ONCOLOGY, INC. Common Stock
- Symbol
- AKTSQ
- Shares outstanding
- 53,160,953 shares
- Disclosed Ownership
- 10,260,064 shares
- Ownership
- 19%
- Form type
- SCHEDULE 13D
- Filing time
- 20 Jan 2026, 17:44:53 UTC
- Date of event
- 12 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"MPM BIOVENTURES 2018, L.P. disclosed 19% ownership in AKTIS ONCOLOGY, INC. Common Stock (AKTSQ) on 12 Jan 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 20 Jan 2026, 17:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (13)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 7.4% | 3,950,528 | 3,950,528 | 0 | /s/ Ansbert Gadicke | Managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the GP of MPM BioVentures 2018, L.P. | 0001729505 |
| MPM BIOVENTURES 2018 (B), L.P. | 0.4% | 206,964 | 206,964 | 0 | /s/ Ansbert Gadicke | Managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the GP of MPM BioVentures 2018(B), L.P. | 0001729504 |
| MPM BioVentures 2018 GP LLC | 7.8% | 4,157,492 | 0 | 4,157,492 | /s/ Ansbert Gadicke | Managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC | 0001818701 |
| MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 0.1% | 77,911 | 77,911 | 0 | /s/ Ansbert Gadicke | Managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC | 0001734817 |
| MPM BioVentures 2018 LLC | 7.9% | 4,235,403 | 0 | 4,235,403 | /s/ Ansbert Gadicke | Managing Director | 0001818702 |
| MPM ONCOLOGY INNOVATIONS FUND LP | 1.6% | 847,080 | 847,080 | 0 | /s/ Ansbert Gadicke | Manager of MPM Oncology Innovations Fund GP LLC, the general partner of MPM Oncology Innovations Fund, L.P. | 0001719960 |
| MPM Oncology Innovations Fund GP LLC | 1.6% | 847,080 | 0 | 847,080 | /s/ Ansbert Gadicke | Manager | 0001857903 |
| Oncology Impact Private Investment Fund 2, L.P. | 9.1% | 4,835,872 | 4,835,872 | 0 | /s/ Ansbert Gadicke | Managing member of MPM Oncology Investments 2 LLC, the general partner of Oncology Impact Private Investment Fund 2, L.P. | 0002104306 |
| MPM Oncology Investments 2 LLC | 9.1% | 4,835,872 | 0 | 4,835,872 | /s/ Ansbert Gadicke | Managing Member | |
| MPM ASSET MANAGEMENT LLC | 0.6% | 341,709 | 341,709 | 0 | /s/ Ansbert Gadicke | Manager | 0001263048 |
| ANSBERT GADICKE | 19% | 10,260,064 | 0 | 10,260,064 | /s/ Ansbert Gadicke | Ansbert Gadicke | 0001134655 |
| LUKE EVNIN | 9.5% | 5,082,483 | 0 | 5,082,483 | /s/ Luke Evnin | Luke Evnin | 0001134657 |
| Todd Foley | 8% | 4,237,506 | 2,103 | 4,235,403 | /s/ Todd Foley | Todd Foley | 0001473930 |